Brokers Set Expectations for VRDN Q1 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Viridian Therapeutics in a research note issued to investors on Tuesday, November 12th. Wedbush analyst L. Chico anticipates that the company will post earnings of ($1.17) per share for the quarter. Wedbush has a "Outperform" rating and a $42.00 price objective on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($3.94) per share. Wedbush also issued estimates for Viridian Therapeutics' Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($1.16) EPS and FY2028 earnings at $9.52 EPS.

A number of other brokerages have also recently commented on VRDN. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. HC Wainwright increased their price objective on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the company a "buy" rating in a report on Thursday. Royal Bank of Canada reissued an "outperform" rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research note on Thursday, September 19th. The Goldman Sachs Group upped their price target on Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, September 12th. Finally, BTIG Research lifted their price objective on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.50.

Viridian Therapeutics Price Performance

VRDN stock traded down $0.84 during midday trading on Thursday, reaching $21.64. The stock had a trading volume of 1,306,484 shares, compared to its average volume of 1,116,568. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05. The company's fifty day simple moving average is $22.35 and its 200 day simple moving average is $16.89. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -5.22 and a beta of 1.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC grew its holdings in shares of Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company's stock valued at $79,000 after purchasing an additional 4,692 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock worth $87,000 after acquiring an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock worth $156,000 after acquiring an additional 2,359 shares during the period. AlphaCentric Advisors LLC raised its stake in shares of Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company's stock valued at $163,000 after acquiring an additional 6,500 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company's stock valued at $171,000 after purchasing an additional 1,688 shares during the period.

Insiders Place Their Bets

In related news, CEO Stephen F. Mahoney bought 21,400 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average price of $23.33 per share, with a total value of $499,262.00. Following the completion of the purchase, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Fairmount Funds Management Llc purchased 1,600,000 shares of Viridian Therapeutics stock in a transaction dated Friday, September 13th. The stock was bought at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the completion of the purchase, the director now directly owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. This trade represents a 86.68 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 1,626,400 shares of company stock valued at $30,616,312 over the last quarter. 0.65% of the stock is owned by insiders.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.